Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lisdexamphetamine treatment of Bulimia Nervosa with and without probable simultaneous Attention Deficit Hyperactivity Disorder (ADHD). A randomized , open, fase II-study with cross-over design. Lisdexamfetaminbehandling vid Bulimia Nervosa med och utan samtidig sannolik Attention Deficit Hyperactivity Disorder (ADHD). En randomiserad, öppen, fas II- studie med cross-over design.

Trial Profile

Lisdexamphetamine treatment of Bulimia Nervosa with and without probable simultaneous Attention Deficit Hyperactivity Disorder (ADHD). A randomized , open, fase II-study with cross-over design. Lisdexamfetaminbehandling vid Bulimia Nervosa med och utan samtidig sannolik Attention Deficit Hyperactivity Disorder (ADHD). En randomiserad, öppen, fas II- studie med cross-over design.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Eating disorders; Mood disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top